CL2024002106A1 - Proteina de fusión de unión a vegf y tie2 - Google Patents
Proteina de fusión de unión a vegf y tie2Info
- Publication number
- CL2024002106A1 CL2024002106A1 CL2024002106A CL2024002106A CL2024002106A1 CL 2024002106 A1 CL2024002106 A1 CL 2024002106A1 CL 2024002106 A CL2024002106 A CL 2024002106A CL 2024002106 A CL2024002106 A CL 2024002106A CL 2024002106 A1 CL2024002106 A1 CL 2024002106A1
- Authority
- CL
- Chile
- Prior art keywords
- fusion protein
- vegf
- binding fusion
- methods
- tie2 binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299177P | 2022-01-13 | 2022-01-13 | |
| US202263310359P | 2022-02-15 | 2022-02-15 | |
| US202263335805P | 2022-04-28 | 2022-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002106A1 true CL2024002106A1 (es) | 2025-03-28 |
Family
ID=87279731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002106A CL2024002106A1 (es) | 2022-01-13 | 2024-07-11 | Proteina de fusión de unión a vegf y tie2 |
| CL2025002473A CL2025002473A1 (es) | 2022-01-13 | 2025-08-18 | Vegf y proteína de fusión de unión a tie2 y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002473A CL2025002473A1 (es) | 2022-01-13 | 2025-08-18 | Vegf y proteína de fusión de unión a tie2 y sus usos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230287109A1 (https=) |
| EP (1) | EP4463482A4 (https=) |
| JP (1) | JP2025503704A (https=) |
| KR (1) | KR20250005053A (https=) |
| AU (1) | AU2023206363A1 (https=) |
| CA (1) | CA3242904A1 (https=) |
| CL (2) | CL2024002106A1 (https=) |
| CO (1) | CO2024010934A2 (https=) |
| CR (1) | CR20240342A (https=) |
| DO (1) | DOP2024000136A (https=) |
| GE (1) | GEAP202416581A (https=) |
| IL (1) | IL314219A (https=) |
| JO (1) | JOP20240158A1 (https=) |
| MX (1) | MX2024008737A (https=) |
| PE (1) | PE20260003A1 (https=) |
| WO (1) | WO2023137395A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025178471A1 (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 맵틱스 | Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359833B (es) * | 2011-08-19 | 2018-10-12 | Regeneron Pharma | Anticuerpos anti-tie2 y usos de los mismos. |
| JP2020501508A (ja) * | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| EP3805265A4 (en) * | 2018-06-07 | 2022-07-06 | Institute for Basic Science | ANTIBODIES BINDING TO TIE2 AND USES THEREOF |
| US10597453B2 (en) * | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| WO2020068653A1 (en) * | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| JP7638989B2 (ja) * | 2019-11-21 | 2025-03-04 | ユニティ バイオテクノロジー インコーポレイテッド | Ｔｉｅ－２に対する抗体および使用方法 |
| AU2021242249A1 (en) * | 2020-03-24 | 2022-08-18 | Genentech, Inc. | Tie2-binding agents and methods of use |
-
2023
- 2023-01-12 KR KR1020247027000A patent/KR20250005053A/ko active Pending
- 2023-01-12 JP JP2024542028A patent/JP2025503704A/ja active Pending
- 2023-01-12 US US18/153,965 patent/US20230287109A1/en active Pending
- 2023-01-12 CR CR20240342A patent/CR20240342A/es unknown
- 2023-01-12 AU AU2023206363A patent/AU2023206363A1/en active Pending
- 2023-01-12 CA CA3242904A patent/CA3242904A1/en active Pending
- 2023-01-12 EP EP23740846.3A patent/EP4463482A4/en active Pending
- 2023-01-12 IL IL314219A patent/IL314219A/en unknown
- 2023-01-12 PE PE2024001601A patent/PE20260003A1/es unknown
- 2023-01-12 MX MX2024008737A patent/MX2024008737A/es unknown
- 2023-01-12 WO PCT/US2023/060582 patent/WO2023137395A1/en not_active Ceased
- 2023-01-12 GE GEAP202416581A patent/GEAP202416581A/en unknown
-
2024
- 2024-07-11 CL CL2024002106A patent/CL2024002106A1/es unknown
- 2024-07-12 DO DO2024000136A patent/DOP2024000136A/es unknown
- 2024-07-14 JO JOJO/P/2024/0158A patent/JOP20240158A1/ar unknown
- 2024-08-12 CO CONC2024/0010934A patent/CO2024010934A2/es unknown
-
2025
- 2025-08-18 CL CL2025002473A patent/CL2025002473A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023137395A1 (en) | 2023-07-20 |
| CL2025002473A1 (es) | 2025-11-14 |
| JOP20240158A1 (ar) | 2024-07-14 |
| PE20260003A1 (es) | 2026-01-06 |
| MX2024008737A (es) | 2024-09-11 |
| EP4463482A4 (en) | 2026-05-06 |
| CO2024010934A2 (es) | 2024-10-31 |
| CR20240342A (es) | 2024-09-18 |
| US20230287109A1 (en) | 2023-09-14 |
| EP4463482A1 (en) | 2024-11-20 |
| IL314219A (en) | 2024-09-01 |
| AU2023206363A1 (en) | 2024-08-15 |
| KR20250005053A (ko) | 2025-01-09 |
| CA3242904A1 (en) | 2025-03-14 |
| JP2025503704A (ja) | 2025-02-04 |
| GEAP202416581A (en) | 2024-12-10 |
| DOP2024000136A (es) | 2024-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002473A1 (es) | Vegf y proteína de fusión de unión a tie2 y sus usos. | |
| CO2020000772A2 (es) | Conjugado de anticuerpo monoclonal contra bcma -fármaco incorporación por referencia de material presentado electrónicamente | |
| CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
| BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| PE20091029A1 (es) | Anticuerpos anti-alfa 5 beta 1 | |
| AR068997A1 (es) | Anticuerpos contra el vegf completamente humano y sus metodos de uso | |
| MX2021004045A (es) | Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco. | |
| UY37457A (es) | Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| EA201992091A1 (ru) | Анти-c5 антитела и их применение | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| MX2021012997A (es) | Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos. | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| BR112023017556A2 (pt) | Anticorpo contra nkp46 e aplicação do mesmo | |
| MX2020010110A (es) | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) |